ADVISORY/First Annual Conference on Regenerative Medicine & Press Conference.News/Assignment Editors & Health/Medical Writers ADVISORY...for Monday (Dec. 4) LARCHMONT, N.Y.--(BW HealthWire)--Nov. 29, 2000 William A. Haseltine, Ph.D., chairman and CEO (1) (Chief Executive Officer) The highest individual in command of an organization. Typically the president of the company, the CEO reports to the Chairman of the Board. of Human Genome Sciences Human Genome Sciences NASDAQ: HGSI is a biopharmaceutical corporation founded in 1992. Its stated purpose is to "discover, develop, manufacture and market innovative drugs that serve patients with unmet medical needs, with a primary focus on protein and antibody drugs. and one of the preeminent pre·em·i·nent or pre-em·i·nent adj. Superior to or notable above all others; outstanding. See Synonyms at dominant, noted. [Middle English, from Latin prae scientists in the burgeoning field of tissue engineering and regenerative re·gen·er·a·tive adj. 1. Of, relating to, or marked by regeneration. 2. Tending to regenerate. re·gen medicine, will hold a special press conference for reporters at the First Annual Conference on Regenerative Medicine on December 4. Dr. Haseltine is chairman of the conference, which will be held at the Renaissance Hotel in Washington, D.C., on December 3-5. The symposium was organized by BioConferences International, Inc., and presented by Mary Ann Liebert, Inc., Publishers, to share the latest news and information on this provocative new field of medicine. Regenerative medicine is a unique new approach to healing that uses genes, proteins, antibodies, and cells to repair organs and tissues. Leading researchers, scientists, physicians, and entrepreneurs in cell biology Cell biology The study of the activities, functions, properties, and structures of cells. Cells were discovered in the middle of the seventeenth century after the microscope was invented. , gene therapy, and tissue engineering will discuss the latest advances in biocompatible materials biocompatible material, n a substance that does not threaten, impede, or adversely affect living tissue. , bioinformatics, cell and stem cell stem cell In living organisms, an undifferentiated cell that can produce other cells that eventually make up specialized tissues and organs. There are two major types of stem cells, embryonic and adult. biology, cloning cloning: see clone. To make a product that functions like another. See clone. See also cloning software. , embryology embryology Study of the formation and development of an embryo and fetus. Before widespread use of the microscope and the advent of cellular biology in the 19th century, embryology was based on descriptive and comparative studies. , gene therapy, genomics, organogenesis organogenesis /or·ga·no·gen·e·sis/ (or?gah-no-jen´e-sis) the origin and development of organs.organogenet´ic or·gan·o·gen·e·sis n. The formation and development of the organs of living things. , transplantation biology Transplantation biology The science of transferring a graft from one part of the body to another or from one individual to another. The graft may consist of an organ, tissue, or cells. If donor and recipient are the same individual, the graft is autologous. , and transplantation medicine during two full days of meetings.
What: First Annual Conference on Regenerative Medicine:
"Regenerative Medicine: A Unique Approach to Healing"
When: December 3-5, 2000. Registration begins at 4:00 PM
Sunday, December 3, followed by an opening reception from
6:00 to 7:30 PM. Registration reopens Monday at 7:45 AM
and sessions begin at 8:45 AM, concluding Tuesday,
December 5, at 4:45 PM.
Where: Renaissance Hotel, 999 Ninth Street N.W., Washington, D.C.
Who: Dr. William A. Haseltine, Chairman & CEO, Human Genome
Sciences, Inc., conference chair, will present the keynote
address, "Regenerative Medicine: A New Medical Paradigm."
These distinguished and widely recognized specialists will
also make presentations: Anthony Atala, M.D., Children's
Hospital/Harvard Medical School; Francois A. Auger, M.D.,
Laboratory of Experimental Organo-genesis, University of
Quebec; Eugene Bell, Ph.D., Tissue Engineering, Inc.;
Michael Blaese, M.D., ValiGen; Vladimir Bobic, M.D., Royal
Liverpool University Hospitals; Arthur Caplan, Ph.D.,
University of Pennsylvania Center for Bioethics; Thomas H.
Fraser, Ph.D., Diacrin, Inc.; Jeffrey M. Isner, M.D., St.
Elizabeth's Medical Center and Tufts University; Hubert
Loewenheim, M.D., University of Tubingen, Germany, and
Otogene AG/Otogene USA; Thomas B. Okarma, Ph.D., M.D.,
Geron Corporation; Ronald McKay, Ph.D., Laboratory of
Molecular Biology, National Institute of Neurological
Disorders & Stroke, National Institutes of Health; Joseph
Rizzo, M.D., Harvard Medical School and Massachusetts Eye
& Ear Infirmary; Craig A. Rosen, Ph.D., Human Genome
Sciences; Michael V. Sefton, Sc.D., University of Toronto;
Evan Y. Snyder, M.D., Ph.D., Children's Hospital, Boston;
Michael D. West, Ph.D., Advanced Cell Technology; and
James M. Wilson, M.D., Ph.D., Institute for Human Gene
Therapy, University of Pennsylvania Medical Center.
Details: For complete information on the conference,
presentation topics, and registration, visit the web site
http://www.bioconferences.com/ebio.
Limited press attendance; PRESS PASS REQUIRED. For press credentials please call or e-mail: BioConferences International, Inc. Harriet I. Matysko, Vice President 914/834-3100 ext. 608 hmatysko@liebertpub.com. |
|
||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion